CureVac Completes Final Chapter as BioNTech Acquisition Concludes

BioNTech finalizes $1.25B acquisition of CureVac, delisting its shares. The deal consolidates mRNA tech, including the RNA Printer, for cancer research.

The era of CureVac operating as an independent, publicly-listed company has officially ended. Following its full acquisition by competitor BioNTech, the German biotech firm’s shares were delisted from the Nasdaq in mid-January. This historic shift in Germany’s biotechnology landscape now turns investor attention toward how CureVac’s technology will be integrated under its new corporate parent.

Transaction Details and Shareholder Impact

BioNTech, based in Mainz, finalized its acquisition of CureVac in December 2025. The legal merger was completed on January 6, 2026, with BioNTech becoming the sole owner of CureVac Merger B.V. The stock was formally removed from the Nasdaq on January 16, 2026.

The all-stock transaction valued CureVac at approximately $1.25 billion, equating to $5.46 per share. This represented a 55% premium over the stock’s average trading price prior to the deal. Through a public tender offer, BioNTech secured about 86.75% of CureVac’s outstanding shares. The remaining equity was transferred in January 2026 via a squeeze-out procedure.

Under the terms, shareholders received 0.05363 BioNTech American Depositary Shares (ADS) for each CureVac share they held. However, investors who did not participate in the initial tender offer faced a financial disadvantage: the BioNTech shares allocated through the squeeze-out were subject to a 15% Dutch dividend withholding tax, a cost avoided by those who accepted the regular offer.

Strategic Rationale and Acquired Assets

This move consolidates key mRNA technology platforms under one roof. BioNTech gains ownership of CureVac’s intellectual property, its manufacturing facilities in Tübingen, and its oncology development pipeline. A central component of the deal is CureVac’s proprietary "RNA Printer" platform for mRNA production, along with algorithms for antigen identification, which are expected to augment BioNTech’s existing capabilities.

CureVac’s last published financial results (Q3 2025) showed the company held €416.1 million in liquid assets. It reported an operating result of €310.2 million, a figure significantly influenced by one-time effects from legal settlements and license adjustments.

Integration and Future Focus

With CureVac’s former leadership team having stepped down upon deal closure, BioNTech is now advancing the integration of its new assets. For investors, access to the Tübingen-developed technology is now only possible indirectly through an investment in BioNTech.

The strategic emphasis for the combined entity is on strengthening mRNA-based cancer research and developing bispecific antibodies. BioNTech aims to leverage the combined expertise and achieve greater scale to compete more effectively in the global biotechnology market.